Browse drugs

…adherence, and safety of long-acting intramuscular cabotegravir/rilpivirine (CAB/RPV) in PLHIV.Material and Methods This was a retrospectiv…

… management, reducing treatment burden and improving adherence. Cabotegravir plus rilpivirine (CAB/RPV LA) is the first complete long-acting…

…osis can be especially challenging in persons using long-acting cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) due to long-acting ear…

…persistence issues remain. Long-acting injectable cabotegravir (CAB-LA) is a promising new PrEP HIV prevention option. However, little…

…V-1 reservoir dynamics of HIV during treatment with long-acting cabotegravir and rilpivirine (LA CAB/RPV) remain limited. This study aimed t…

…/TDF) were assessed by a multivariable logistic regression. For CAB-LA, injections were classified as on time (within ±7 days from the…

…Background Long-acting cabotegravir plus rilpivirine (CAB+RPV) is the first intramuscular antiretro…

…nter study enrolled PLWH who switched to bimonthly LAI-ART with cabotegravir (CAB) and rilpivirine (RPV) between January 2023 and October 20…

…Background Long-acting (LA) cabotegravir (CAB) and rilpivirine (RPV) is an effective and well-tolerated antiretroviral switch …

…Introduction Cabotegravir + rilpivirine long-acting regimen (CARLA) has no anti-HBV activ…

…ve access and persistence. Long-acting injectable cabotegravir (CAB-LA) has recently been introduced in some Italian clinical centres,…

…isoproxil fumarate/emtricitabine in all age groups. Long-acting cabotegravir was used more often with increasing age (9.8% in <50, 11.5% in …